title: Solid lipid nanoparticles for ocular drug delivery.
abstract: Ocular drug delivery remains challenging because of the complex nature and structure of the eye. Conventional systems, such as eye drops and ointments, are inefficient, whereas systemic administration requires high doses resulting in significant toxicity. There is a need to develop novel drug delivery carriers capable of increasing ocular bioavailability and decreasing both local and systemic cytotoxicity. Nanotechnology is expected to revolutionize ocular drug delivery. Many nano-structured systems have been employed for ocular drug delivery and yielded some promising results. Solid lipid nanoparticles (SLNs) have been looked at as a potential drug carrier system since the 1990s. SLNs do not show biotoxicity as they are prepared from physiological lipids. SLNs are especially useful in ocular drug delivery as they can enhance the corneal absorption of drugs and improve the ocular bioavailability of both hydrophilic and lipophilic drugs. SLNs have another advantage of allowing autoclave sterilization, a necessary step towards formulation of ocular preparations. This review outlines in detail the various production, characterization, sterilization, and stabilization techniques for SLNs. In-vitro and in-vivo methods to study the drug release profile of SLNs have been explained. Special attention has been given to the nature of lipids and surfactants commonly used for SLN production. A summary of previous studies involving the use of SLNs in ocular drug delivery is provided, along with a critical evaluation of SLNs as a potential ocular delivery system.
authors.affiliation: University of Auckland, Faculty of Medical and Health Sciences, School of Pharmacy, Auckland, New Zealand.
authors.forename: Ali
authors.initials: A
authors.lastname: Seyfoddin
authors.forename: John
authors.initials: J
authors.lastname: Shaw
authors.forename: Raida
authors.initials: R
authors.lastname: Al-Kassas
mesh_terms: D000287:Administration, Topical; D002626:Chemistry, Pharmaceutical; D003315:Cornea / Q000378:metabolism*; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D053758:Nanoparticles; D009883:Ophthalmic Solutions; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry*
chemical_list: D008055:Lipids; D009883:Ophthalmic Solutions; D004364:Pharmaceutical Preparations; D013501:Surface-Active Agents